Long‐term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction

Pannek, Jürgen; Göcking, K; Bersch, Ulf

doi:10.1111/j.1464-410x.2009.08600.x

Cited by 63 publications

(44 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BoNT is a promising treatment for lower urinary tract dysfunction with profound basic and clinical implications [30] . Pannek et al [31] demonstrated the long-term efficacy of BoNT-A in neurogenic detrusor overactivity. On the contrary, Schulte-Baukloh et al raised the important subject of BoNT-A antibodies and therapy failure after long-term use of BoNT-A [32] .…”

Section: Reviewmentioning

confidence: 99%

The Unusual History and the Urological Applications of Botulinum Neurotoxin

Hanchanale

Rao²,

Martin³

et al. 2010

Urol Int

View full text Add to dashboard Cite

Introduction: Botulinum neurotoxin (BoNT) is probably the most potent biological toxin that can affect humans. Since its discovery by Justinus Kerner, BoNT has seen use in a wide range of cosmetic and non-cosmetic conditions such as cervical dystonia, cerebral palsy, migraines and hyperhidrosis. We tried to trace its history from its inception to its recent urological applications. Materials and Methods: Historical articles about botulinum toxin were reviewed and a Medline search was performed for its urological utility. We hereby present a brief review of historical aspects of BoNT and its applications in urology. Results: In 1793, the first known outbreak of botulism occurred due to ‘spoiled’ sausage in Wildebad, Germany. The German physician and poet Justinus Kerner published the first accurate description of the clinical symptoms of botulism (sausage poison). He was also the first to mention its potential therapeutic applications. In urology, BoNT has been used in bladder and urethral lesions with varying degree of success. Recently, BoNT applications were explained for prostatic disorders. BoNT applications in urology are in the treatment of detrusor external sphincter dyssynergia, detrusor overactivity, detrusor underactivity, spastic conditions of the urethral sphincter, chronic prostate pain, interstitial cystitis, non-fibrotic bladder outflow obstruction (including benign prostatic hyperplasia) and acute urinary retention in women. Conclusion: Justinus Kerner is the godfather of botulism research. The role of BoNT in urology has evolved exponentially and it is widely used as an adjuvant in voiding dysfunction. In the future, its utility will broaden and guide the urologist in managing various urological disorders.

show abstract

Section: Reviewmentioning

confidence: 99%

The Unusual History and the Urological Applications of Botulinum Neurotoxin

Hanchanale

Rao²,

Martin³

et al. 2010

Urol Int

View full text Add to dashboard Cite

show abstract

“…Nach der ersten Injektionstherapie zeigte sich eine Kontinenzrate von 93%, welche im Studienverlauf auf 74% nach der jeweils letzten Injektion abfiel [18].…”

Section: Risikofaktorenunclassified

Überaktive Blase, Neurourologie, Urogynäkologie und Belastungsinkontinenz

Reiter

Oeztuerk

Kurosch

et al. 2010

Urologe

View full text Add to dashboard Cite

The current review presents a summary of the most important manuscripts concerning the topics of overactive bladder, neurourology, genital prolapse and male and female urinary stress incontinence published in the year 2009 and the first 4 months of 2010 in peer-reviewed journals. The literature research was focussed on clinically relevant human studies with influence on diagnosis and therapeutic strategies of these diseases.Most of the published manuscripts focussed on the fields of overactive bladder and female urinary stress incontinence during the last 16 months. Some of the studies had very high evidence levels and confirmed new therapeutic strategies. Publications focussing on male urinary stress incontinence were of limited numbers in the year 2009 and did not change the clinical armamentarium significantly.

show abstract

“…Pannek et al [44] treated 27 patients with SCI with at least 5 (mean, 7.1) successive BTX-A injections. Continued efficacy was observed over time, with 74% considered to be treatment successes (based on urodynamic compliance and storage pressures as well as continence status).…”

Section: Botulinum Toxinmentioning

confidence: 99%